Clinical Significance and Predictive Value of Prostaglandin E2 Receptors (EPR) 1 – 4 in Patients with Renal Cell Carcinoma

  1. HIDEKI SAKAI1
  1. 1Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
  2. 2Department of Pathology, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki 853-8501, Japan
  3. 3Department of Experimental and Clinical Laboratory Medicine, National Hospital Organization, Nagasaki Hospital, Sakuragi-cho 6-41, Nagasaki 850-8523, Japan
  1. Correspondence to: Yasuyoshi Miyata, MD, Ph.D., Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Tel: +81 958497340, Fax: +81 958497343, e-mail: int.doc.miya{at}m3.dion.ne.jp

Abstract

Background: The clinical significance of prostaglandin E2 receptor (EPR) expression in renal cell carcinoma (RCC) tissues remains unclear. Patients and Μethods: Four subtypes of EPRs were examined in 112 human RCC tissues by immunohistochemical and Western blot analysis. The relationships between EPR immunoreactivity score (IS) and various pathological features and survival were then analyzed. Results: The IS of EP4R was significantly higher (p<0.001) in cancer cells (mean=2.7 and SD=2.1) than in normal kidney tissues (1.8 and 1.2). EP4R expression correlated with pT stage, metastasis, and grade. EP2R expression was also associated with metastasis. Expressions of both EP2R and EP4R were found to be significant predictors for cause-specific survival on Kaplan-Meier survival analysis (p=0.006 and 0.023, respectively). Conclusion: EP2R and EP4R may play important roles in malignant behavior. EP4R in particular was closely associated with pathological features, implicating this receptor as a potential therapeutic target in patients with RCC.

  • Received December 6, 2010.
  • Revision received January 12, 2011.
  • Accepted January 13, 2011.
| Table of Contents

This Article

  1. Anticancer Research vol. 31 no. 2 597-605
  1. » AbstractFree
  2. Figures OnlyFree
  3. Full TextFree
  4. Full Text (PDF)Free

Classifications

Current Issue

  1. August 2019, 39 (8)
  1. Alert me to new issues of Anticancer Research

Most